| Drug Name |
Quinapril |
| Drug ID |
BADD_D01890 |
| Description |
Quinapril is the ethyl ester prodrug of the non-sulfhydryl angiotensin converting enzyme inhibitor quinaprilat.[L8420,L8423] It is used to treat hypertension and heart failure.[L8420,L8423] ACE inhibitors are commonly used as a first line therapy in the treatment of hypertension, along with thiazide diuretics or beta blockers.[A184844]
Quinapril was granted FDA approval on 19 November 1991.[L8420] A combination tablet with [hydrochlorothiazide] was also approved on 28 December 1999.[L8423] |
| Indications and Usage |
Quinapril is indicated for the treatment of hypertension and as an adjunct therapy in the treatment of heart failure.[L8420] Quinapril in combination with hydrochlorothiazide is indicated for the treatment of hypertension.[L8423] |
| Marketing Status |
approved; investigational |
| ATC Code |
C09AA06 |
| DrugBank ID |
DB00881
|
| KEGG ID |
D03752
|
| MeSH ID |
D000077583
|
| PubChem ID |
54892
|
| TTD Drug ID |
D0I7SZ
|
| NDC Product Code |
50090-5165; 68001-260; 50090-5400; 68084-899; 69097-841; 71335-1262; 57297-555; 69097-839; 71335-1134; 71335-1441; 43547-412; 68180-557; 70934-964; 68001-189; 69097-843; 71205-635; 63187-425; 63629-8710; 68001-188; 71205-484; 68001-187; 68180-554; 68180-556; 71335-1707; 51655-737; 68180-558; 69097-842; 43547-411; 43547-413 |
| UNII |
RJ84Y44811
|
| Synonyms |
Quinapril | 2-(2-((1-(Ethoxycarbonyl)-3-phenylpropyl)amino)-1-oxopropyl)-1,2,3,4-tetrahydro-3-isoquinolinecarboxylic acid | Accupril | CI 906 | CI-906 | Quinapril Hydrochloride | PD 109452-2 | PD 109452 2 | PD 1094522 | PD-109,452-2 | PD 109,452 2 |
